Accelerating Synthetic & Phytocannabinoid Research & Development into Clinical Approvals for Neurological, Pain, Inflammatory Indications & More

Your Definitive Forum for Navigating the Clinical Pathway of Cannabinoid Therapies

Realising the Potential of Endocannabinoid-System-Targeted & Cannabinoid Therapies

Struggling to navigate complex scientific, regulatory, and commercial challenges to bring safe, effective cannabinoid-based medicines to patients in need?

The 8th Cannabinoid & Endocannabinoid Drug Development Summit uniquely brings together 60+ leading experts from preclinical research, clinical trials, pharmacology, regulatory affairs, and intellectual property- offering a comprehensive, multidisciplinary platform.

Covering diverse therapeutic areas, from neurology and inflammation to endometriosis, join to engage in critical discussions, forge strategic partnerships, and gain the knowledge needed to overcome key hurdles in clinical development.

Now is the time to connect, collaborate, and drive forward the next generation of clinically validated cannabinoid therapies with pioneering experts from Ananda, Synendos, Indication BioSciences, Nalu Bio and more.

VIEW THE FULL EVENT GUIDE!

World-Class Speaker Faculty Includes:

Previously Attending Companies Include:

jazzpharma_logo_fullcolor
Roche_Logo.svg
Artelo
avecho
Alterola
neurotherapia
isosceles
mira pharmaceuticals
GbSciences_Logo_2021.09.23_websize
avicanna
nalu bio
Indication Bioscience
Andira
auxilio pharma

Top Testimonial:

Along with exposure to the latest innovation in cannabinoid field, this conference addressed the regulatory governance and gaps in this area followed by what’s being done to expedite research in this area.

-Medcann Limited, founder Dr Parveen Bhatarah

Our Partners:

Expertise Partner

Transpharmation

Innovation Partners

Citra Chem

Exhibition Partners

Carmen's Medicinals
Triverity labs

Other Events In The Series: